GlobeNewswire

GOGL - Agreement for construction of three Kamsarmax vessels

Share

Golden Ocean Group Limited (Nasdaq and OSE: GOGL) ("Golden Ocean" or the "Company"), one of the world's largest listed dry bulk shipowners, today announces that it has entered into an agreement for the construction of three high-specification latest generation 85,000 dwt ECO-type Kamsarmax vessels, which will be constructed at a first-class Chinese yard. The vessels will be equipped with the latest and most efficient propulsion system, contributing with significant improvements in fuel consumption and emissions performance. The vessels are dual-fuel ready, giving the Company time to evaluate alternatives while the visibility of future regulations and optimal technology improves.

The vessels are scheduled to deliver from Q3–2023 to Q1-2024. Golden Ocean intends to finance the acquisition with operating cash flow and cash on hand and will establish long-term debt financing closer to delivery.

Ulrik Andersen, CEO of Golden Ocean Management AS commented:

"With this transaction, we continue executing on our strategy of renewing the fleet and improving its operating performance. At the same time, it underlines our belief in the long-term dry bulk fundamentals.

We have secured an attractive price with a tail-heavy payment structure, which means Golden Ocean can absorb the transaction without impacting the Company's dividend capacity, which continues to be a key priority. The vessels benefit from additional cargo intake, and the superior fuel economy will ensure low operating costs and a reduced carbon footprint.

September 9, 2021

The Board of Directors
Golden Ocean Group Ltd.
Hamilton, Bermuda

For further queries, please contact:

Ulrik Andersen: Chief Executive Officer, Golden Ocean Management AS
+47 22 01 73 53

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Forward-looking statements:

This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release

After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid

Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release

September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0

21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release

Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto

Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release

Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665

Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release

PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release

CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic